Mobosetinib/Mobosetinib latest price 2024

Mobocertinib/Mobocertinib is an irreversible small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to selectively target EGFR and HER2 (ERBB2) exon20 insertion mutants. Mobosetinib and its two active metabolites AP32960 and AP32914 have roughly the same effect in inhibiting EGFR.

Mobosetinib mainly targets non-small cell lung cancerEGFR exon 20 insertion mutants. Through iterative structure-guided platform design, it targetsEGFRex20ins mutation and shows anti-tumor activity in metastatic, previously treated NSCLC patients carrying EGFRex20s mutations. Although the analysis included a small number of patients, mobosertinib 160 mg daily showed a high response rate (43%) and good median progression-free survival (7.3 months).

Based on data from healthy subjects, it is shown that a low-fat meal (≤350 calories and ≤15% of calories from fat) has no effect onthe pharmacokinetics (PK) of mobosertinib. The adverse events of mobosetinibare similar to those of other EGFR inhibitors and are generally characterized by gastrointestinal and cutaneous adverse events.

The original drug of mobosetinib has been officially sold in China, but unfortunately, it has not been included in the scope of medical insurance. Currently, the common 40 mg 112-capsule format on the market sells for about 40,000 yuan per box, which is quite expensive. In comparison, the clinical version in Hong Kong is priced at more than 7,000 yuan per box of 40mg and 30 capsules. The specific price may fluctuate due to exchange rate changes. At the same time, generic drugs of Mobotinib have been sold in overseas markets, and their ingredients are roughly the same as the original drugs at home and abroad. For example, a box of 40mg*120 tablets produced by a pharmaceutical factory in Laos may cost only more than 4,000 yuan per box. Of course, the price may also be adjusted due to exchange rate changes.